Medicenna Announces Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer’s (SITC)

TORONTO and HOUSTON, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ, TSX: MDNA), a clinical-stage immunotherapy company focused on the development of Superkines, announced poster presentations at the 38^th Annual Meeting of the Society for Immunotherapy of Cancer (“SITC”) to be held in San Diego, CA, from November 1-5^th, 2023.

Read more at globenewswire.com